MARKET

REGN

REGN

Regeneron Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

369.53
+3.90
+1.07%
Opening 12:40 12/10 EST
OPEN
357.15
PREV CLOSE
365.63
HIGH
372.15
LOW
357.00
VOLUME
531.61K
TURNOVER
--
52 WEEK HIGH
442.00
52 WEEK LOW
271.37
MARKET CAP
40.57B
P/E (TTM)
20.30
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of REGN and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 24 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

REGN News

  • Regeneron Shares Swing On Sanofi's Hint At Sale Of Ownership Stake, Amendments To Drug Collaborations
  • Benzinga.12m ago
  • Regeneron shares fall on Sanofi's new direction
  • MarketWatch.3h ago
  • Sanofi Unveils Growth Strategy, Ends Diabetes & CV Research
  • Zacks.3h ago
  • Regeneron and Sanofi Announce Intent to Restructure Antibody Collaboration for Kevzara® (sarilumab) and Praluent® (alirocumab)
  • PR Newswire.4h ago

More

Industry

Biotechnology & Medical Research
+0.71%
Pharmaceuticals & Medical Research
+0.71%

Hot Stocks

Name
Price
%Change

About REGN

Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases. The Company's marketed products include EYLEA (aflibercept) Injection, Praluent (alirocumab) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use, Kevzara (sarilumab) Solution for Subcutaneous Injection and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. As of December 31, 2016, the Company had 16 product candidates in clinical development, which consisted of a Trap-based clinical program and 15 fully human monoclonal antibody product candidates.
More

Webull offers Regeneron Pharmaceuticals Inc (REGN) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.